Continued appetite for neuroscience assets drives deal; pharma rebuilding in an area where it has become less reliant in recent years

Emerging class could find niche among patients whose major depressive disorder includes symptoms of anhedonia

Plus: Wu Changxiong succeeds Zhou Hua as CFO of Walvax, and updates from Hookipa, Janux, Akeso and Serina

Plus: Bodmer to lead Nucleome as CEO and updates from Nouscom, Oxford Biomedica and Aslan

Continuing diversity push under Viehbacher, Biogen obtains two programs spun out from MorphoSys, backed by Arch, Monograph, Jeito and others

Largest upfront M&A payment for a preclinical biotech in three years 

BioCentury’s weekly roundup of biopharma deals, Jan. 30- Feb. 5

Plus: Psychedelic play MAPS rebrands as Lykos, HI-Bio raises a series B, and more cash goes to China-based biotechs

Plus: Regulatory delay for BMS, 2seventy’s Abecma, and updates from AstraZeneca and Ibiome

Plus: Takeda’s fruquintinib approved for colorectal cancer, and updates from Forward, Ascidian, Xencor, UltraDx and more